{"page_content": "ESG R eport 2022\nAt Agios, we are committed to building a sustainable business that provides long-\nterm value for all our stakeholders. We support environmental, social and governance \n(ESG) initiatives that are aligned with our culture and values and that may positively \nimpact the patients we serve, our employees, our communities and our world.\nThis document contains disclosure of sustainability metrics relevant to Agios\u2019 \nbusiness and strategy. These metrics are aligned with the Sustainability \nAccounting Standards Board (SASB) standards for the Biotechnology and \nPharmaceuticals Industry and the United Nations Sustainable Development \nGoals (UN SDGs). Unless otherwise noted, it covers ESG disclosures for Agios \nPharmaceuticals for the period Jan. 1, 2021 through Dec. 31, 2021.\nAgios Pharmaceuticals \nCorporate  Sustainability  Tear Sheet\n2", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 1, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}